James E Deerfield Mgmt Iv, ... Net Worth

The estimated Net Worth of James E Deerfield Mgmt Iv, ... is at least $7.77 million dollars as of 14 July 2020. James Iv owns over 1,000,000 units of Nkarta stock worth over $7,767,789 and over the last 5 years James sold NKTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James Iv NKTX stock SEC Form 4 insiders trading

James has made over 3 trades of the Nkarta stock since 2020, according to the Form 4 filled with the SEC. Most recently James bought 1,000,000 units of NKTX stock worth $18,000,000 on 14 July 2020.

The largest trade James's ever made was buying 1,000,000 units of Nkarta stock on 14 July 2020 worth over $18,000,000. On average, James trades about 462,500 units every 39 days since 2020. As of 14 July 2020 James still owns at least 1,209,936 units of Nkarta stock.

You can see the complete history of James Iv stock trades at the bottom of the page.

Insiders trading at Nkarta

Over the last 4 years, insiders at Nkarta have traded over $2,620,353 worth of Nkarta stock and bought 14,255,554 units worth $205,999,973 . The most active insiders traders include Plc Gsk, Ali Behbahani et Holdings A/S Novo. On average, Nkarta executives and independent directors trade stock every 24 days with the average trade being worth of $1,501,195. The most recent stock trade was executed by Alicia J. Hager on 16 July 2024, trading 3,396 units of NKTX stock currently worth $27,168.

What does Nkarta do?

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Complete history of James Iv stock trades at Revolution Medicines Inc, DFP Healthcare Acquisitions, Schrodinger et Nkarta

Nkarta executives and stock owners

Nkarta executives and other stock owners filed with the SEC include:

• Paul J. Hastings,
  CEO, Pres & Director
• Dr. Nadir Mahmood Ph.D.,
  Chief Financial & Bus. Officer
• Dr. Alicia J. Hager,
  Chief Legal Officer & Corp. Sec.
• Dr. Kanya Rajangam,
  Chief Medical Officer
• Greg Mann,
  VP of Public Affairs and Investor Relations
• Dr. James Trager Ph.D., Ph.D.,
  Chief Scientific Officer
• Dr. Ralph Brandenberger Ph.D.,
  Sr. VP of Technical Operations
• Zachary Scheiner,
  
• Leone D Patterson,
  
• David Shook,
  See Remarks
• George Vratsanos,
  
• Michael Dybbs,
  
• Ali Behbahani,
  
• Nadir Mahmood,
  President
• Laura Shawver,
  Director
• Kanya Rajangam,
  Chief Medical Officer
• Fouad Oscar Azzam,
  Director
• Matthew Plunkett,
  Chief Financial Officer
• James Trager,
  Chief Scientific Officer
• James E Deerfield Mgmt Iv, ...,
  
• Capital Management, L.P.Ra ...,
  
• Capital Management, L.P.Kol...,
  
• Holdings A/S Novo,
  10% owner
• Simeon George,
  
• Plc Gsk,
  Director
• Angela Thedinga,
  
• Ralph Brandenberger,
  Chief Technical Officer
• Alicia J. Hager,
  Chief Legal Officer
• Paul J Hastings,
  Chief Executive Officer
• Capital Management, L.P.Ra ...,
  
• Tiba Aynechi,
  Director
• Alyssa Levin,
  See Remarks